Compare DraftKings Inc (DKNG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Moderna, Inc. — how do they compare? DraftKings Inc trades at $19.58 (market cap $9.86B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 8× DraftKings Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Moderna, Inc. for 59 Days on average.
| DKNG | MRNA | |
|---|---|---|
Market Cap | $9.86B | $78.65B |
Volume | 16,584,596 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $225.00 |
52-Week Low | $18.59 | $22.36 |
Typical Hold Time | 55 Days | 59 Days |
Enterprise Value | $10.80B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.87, down 3.76% but showing signs of fundamental improvement with revenue growth from $2.2B in 2022 to $6.05B in 2025 and achieving its first profitable year. The stock faces technical bearish signals with recent price weakness, hitting a new 52-week low near $19 support levels. Recent news highlights the company's DKeX rollout and NHL partnership while facing margin concerns from prediction market investments.
Despite current bearish technicals, DKNG's path to profitability and strong analyst consensus ($33.13 price target, 75% buy ratings) suggest long-term potential. Key risks include high valuation multiples (P/E 246.33), competitive pressures, and regulatory uncertainty in sports betting markets. The company's $1B EBITDA target for 2026 and prediction market expansion provide growth catalysts if execution succeeds.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
